- Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for people with certain types of Non-Hodgkin's Lymphoma that have come back or not responded to previous treatments. It aims to check safety and how well the new treatments work.
For: Lymphoma, Non-HodgkinUnited States · Australia · Belgium - Active not recruitingPHASE3
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug, glofitamab, combined with standard chemotherapy (GemOx) for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this new combination to a standard treatment.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
This study compares two treatments for chronic lymphocytic leukaemia (CLL), a type of blood cancer. We're looking at whether a new combination (sonrotoclax with zanubrutinib) works better than a standard one (venetoclax with obinutuzumab) in people who haven't had treatment before.
For: CLLUnited States · Australia · Austria - RecruitingPHASE3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
This study looks at new drug combinations for adults in the UK with a type of blood cancer called chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It compares new treatments with current ones to see which works best and is safest for patients whose cancer has come back or not responded to previous treatments.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Argentina · Australia - RecruitingPHASE2
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
This study looks at a new way to re-treat a type of blood cancer called CLL when it returns. It uses two approved medicines, venetoclax and obinutuzumab, in adults who have had previous venetoclax treatment.
For: Chronic Lymphocytic Leukemia (CLL)United States · Australia · Austria - Active not recruitingPHASE3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
This study is testing new treatments for two types of lymphoma, follicular and marginal zone lymphoma, when they have come back or not responded to previous treatment. It compares a drug called zanubrutinib combined with other medicines against a standard treatment to see which works best.
For: Relapsed/Refractory Follicular Lymphoma · Marginal Zone LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
This study is testing a new medicine, glofitamab, for people in the UK with a type of blood cancer called mantle cell lymphoma. It aims to see if glofitamab works better than standard treatments for those whose cancer has returned or isn't responding to past therapies.
For: LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
For: Follicular Lymphoma (FL)United States · Australia · Belgium - RecruitingPHASE2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
This study is looking at a new medicine called obinutuzumab for teenagers and children aged 5 to 17 with a kidney condition called lupus nephritis. We want to see if it's safe, how well it works, and how the body uses it.
For: Lupus NephritisUnited States · Brazil · Canada - RecruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
This study is testing new combinations of medicines for a type of blood cancer called Non-Hodgkin Lymphoma. It aims to see how safe and effective these new treatments are, and how the body handles them. It's for people whose cancer hasn't responded well to previous treatments.
For: Non-Hodgkin LymphomaUnited States · Israel · Italy - RecruitingPHASE2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The REFRACT trial explores new treatments for follicular lymphoma that has come back or not responded to previous therapy. It compares new drugs with standard care to see if they offer better results for patients.
For: Relapsed Follicular Lymphoma · Refractory Follicular LymphomaUnited Kingdom - Active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
This study looks at new drug combinations for people with newly diagnosed chronic lymphocytic leukemia (CLL). It compares these new treatments, acalabrutinib and venetoclax (with or without obinutuzumab), to standard chemotherapy to see which works best and is safest.
For: Chronic Lymphocytic LeukemiaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This study is looking at two different medicine combinations for people with a type of blood cancer called chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). We want to see if a newer treatment works better at stopping the cancer from growing.
For: Leukemia, Lymphocytic, Chronic, B-CellUnited States · Belgium · Canada - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
This study is looking at a new medicine called obinutuzumab for people with a serious kidney problem called lupus nephritis. Researchers want to see if it's safe and helps better than a dummy medicine when added to usual treatments, like steroids.
For: Lupus NephritisUnited States · Argentina · Brazil - Active not recruitingPHASE1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
This study is testing new combinations of anti-cancer medicines for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. It aims to find safe doses and see how well these new combinations work.
For: B-Cell Non-Hodgkin Lymphoma · Relapsed B-Cell Non-Hodgkin Lymphoma · Refractory B-Cell Non-Hodgkin LymphomaUnited States · Belgium · Czechia - Active not recruitingPHASE3
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
This study tested new treatments for Chronic Lymphocytic Leukemia (CLL), a type of blood cancer, in people who had not been treated before. It compared different drug combinations to see which worked best to slow down or stop the cancer's progress.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Belgium - RecruitingPHASE2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This study looks at a new way to give a treatment called glofitamab, along with gemcitabine and oxaliplatin, for a type of blood cancer called B-cell non-Hodgkin's lymphoma. The goal is to make the treatment safer and easier to get, potentially as an outpatient.
For: B-Cell Non-Hodgkins LymphomaUnited States · Australia · Canada - RecruitingPHASE3
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
This study looks at new ways to treat Chronic Lymphocytic Leukemia (CLL), a type of blood cancer. Researchers are testing the safety of two drug combinations: venetoclax with obinutuzumab, or venetoclax with acalabrutinib. They want to see how well these treatments work and if they cause any side effects.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · France - RecruitingPHASE3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
This study is testing a new combination of drugs, mosunetuzumab and lenalidomide, for follicular lymphoma. It compares this new treatment to standard chemotherapy for people who haven't had treatment before. The aim is to see if the new combination works better and is safe.
For: Follicular LymphomaAustria · Belgium · France - Active not recruitingPHASE3
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two treatments, Acalabrutinib plus Venetoclax vs. Venetoclax plus Obinutuzumab, for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's checking which combination works better and is safer.
For: Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaUnited States · Australia · Czechia - Active not recruitingPHASE2
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
This study is testing a new combination of medicines for older or less fit patients with a type of aggressive B-cell lymphoma who haven't had treatment before. The aim is to see if this new approach, called R-Pola-Glo, is safe and effective.
For: Lymphoma, Large B-Cell, DiffuseAustria · Germany - Active not recruitingPHASE1
Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
This study is testing a new medicine called sonrotoclax for certain blood cancers like lymphoma and leukaemia. We want to find the safest and most effective dose, both on its own and when combined with other medicines, to help patients with these conditions.
For: Mature B-Cell MalignanciesUnited States · Australia · Germany - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
This study is looking into a new treatment called Obinutuzumab for a condition called lupus (Systemic Lupus Erythematosus). It compares this new treatment with a dummy treatment (placebo) to see if it's safe and effective for people already getting standard lupus care.
For: Systemic Lupus ErythematosusUnited States · Argentina · Brazil - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
This study is looking at a new treatment called Obinutuzumab for a kidney condition called primary membranous nephropathy (pMN). It's a Phase 3 study, meaning it's well into testing, to see if this new medicine works better and is safer than current treatments.
For: Primary Membranous NephropathyUnited States · Argentina · Brazil - Active not recruitingPHASE1, PHASE2
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for adults with a type of blood cancer called Non-Hodgkin's Lymphoma that has come back or not responded to previous treatments. It aims to find the safest dose and see how well these new treatments work.
For: Non-Hodgkins LymphomaBelgium · Denmark · Israel - RecruitingPHASE1, PHASE2
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
This study looks at a new drug, BGB-16673, combined with other medicines for people with B-cell cancers that have come back or not responded to past treatments. It checks how safe and effective these combinations are.
For: B-cell Malignancy · Relapsed Cancer · Refractory CancerUnited States · Australia · Brazil - RecruitingPHASE3
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
This study compares two treatments for high-risk chronic lymphocytic leukaemia (CLL). One involves three drugs, and the other uses two. It aims to see if the three-drug combination can better prevent the disease from getting worse.
For: Chronic Lymphocytic LeukemiaGermany - RecruitingPHASE2
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
This study looks at new drug combinations for large B-cell lymphoma that has come back or not responded to past treatments. It checks how safe and effective these drugs are, both before and after a treatment called CAR-T cell therapy.
For: Large B-cell LymphomaUnited Kingdom - Active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
For: Lymphoma, Non-HodgkinUnited States · Argentina · Austria